Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ibio ( (IBIO) ) has provided an update.
iBio, Inc. announced an extension of the maturity date for a $1,500,000 promissory note issued to Safi Biotherapeutics Inc. Originally set to mature on June 19, 2025, the maturity date has now been extended to June 19, 2026, contingent upon the payment of all accrued interest at the time of extension. This extension provides iBio with additional financial flexibility and may impact its financial planning and stakeholder relations.
The most recent analyst rating on (IBIO) stock is a Buy with a $3.60 price target. To see the full list of analyst forecasts on Ibio stock, see the IBIO Stock Forecast page.
Spark’s Take on IBIO Stock
According to Spark, TipRanks’ AI Analyst, IBIO is a Neutral.
IBIO’s overall score is heavily impacted by significant financial challenges, including negative earnings and cash flow issues. The weak technical outlook and poor valuation metrics further weigh down the score. However, recent strategic corporate events provide some optimism for future growth, but they are not enough to offset the current financial difficulties.
To see Spark’s full report on IBIO stock, click here.
More about Ibio
Average Trading Volume: 1,107,499
Technical Sentiment Signal: Sell
Current Market Cap: $14.18M
Learn more about IBIO stock on TipRanks’ Stock Analysis page.